<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36549578</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2139</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Brain, behavior, and immunity</Title><ISOAbbreviation>Brain Behav Immun</ISOAbbreviation></Journal><ArticleTitle>Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction.</ArticleTitle><Pagination><StartPage>302</StartPage><EndPage>308</EndPage><MedlinePgn>302-308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbi.2022.12.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0889-1591(22)00475-5</ELocationID><Abstract><AbstractText>Persistent olfactory dysfunction (OD) is one of the most complaining and worrying complications of long COVID-19 because of the potential long-term neurological consequences. While causes of OD in the acute phases of the SARS-CoV-2 infection have been figured out, reasons for persistent OD are still unclear. Here we investigated the activity of two inflammatory pathways tightly linked with olfaction pathophysiology, namely Substance P (SP) and Prokineticin-2 (PK2), directly within the olfactory neurons (ONs) of patients to understand mechanisms of persistent post-COVID-19 OD. ONs were collected by non-invasive brushing from ten patients with persistent post-COVID-19 OD and ten healthy controls. Gene expression levels of SP, Neurokinin receptor 1, Interleukin-1&#x3b2; (IL-1&#x3b2;), PK2, PK2 receptors type 1 and 2, and Prokineticin-2-long peptide were measured in ONs by Real Time-PCR in both the groups, and correlated with residual olfaction. Immunofluorescence staining was also performed to quantify SP and PK2 proteins. OD patients, compared to controls, exhibited increased levels of both SP and PK2 in ONs, the latter proportional to residual olfaction. This work provided unprecedented, preliminary evidence that both SP and PK2 pathways may have a role in persistent post-COVID-19 OD. Namely, if the sustained activation of SP, lasting months after infection's resolution, might foster chronic inflammation and contribute to hyposmia, the PK2 expression could instead support the smell recovery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schirinzi</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Italy. Electronic address: t.schirinzi@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lattanzi</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maftei</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grillo</LastName><ForeName>Piergiorgio</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zenuni</LastName><ForeName>Henri</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boffa</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonetta</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bovenzi</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurizi</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loccisano</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincenzi</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Sense Organs, Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Girolamo</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercuri</LastName><ForeName>Nicola B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passali</LastName><ForeName>Francesco M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Severini</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Behav Immun</MedlineTA><NlmUniqueID>8800478</NlmUniqueID><ISSNLinking>0889-1591</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33507-63-0</RegistryNumber><NameOfSubstance UI="D013373">Substance P</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423608">PROK2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="Y">Olfaction Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013373" MajorTopicYN="N">Substance P</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anosmia</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hyposmia</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Olfactory dysfunction</Keyword><Keyword MajorTopicYN="N">Olfactory neurons</Keyword><Keyword MajorTopicYN="N">Prokineticin-2</Keyword><Keyword MajorTopicYN="N">Substance P</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36549578</ArticleId><ArticleId IdType="pmc">PMC9760596</ArticleId><ArticleId IdType="doi">10.1016/j.bbi.2022.12.017</ArticleId><ArticleId IdType="pii">S0889-1591(22)00475-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bao Z., Liu Y., Chen B., Miao Z., Tu Y., Li C., Chao H., Ye Y., Xu X., Sun G., Zhao P., Liu N., Liu Y., Wang X., Lam S.M., Kagan V.E., Bay&#x131;r H., Ji J. Prokineticin-2 prevents neuronal cell deaths in a model of traumatic brain injury. Nat. Commun. 2021;12 doi: 10.1038/S41467-021-24469-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41467-021-24469-Y</ArticleId><ArticleId IdType="pmc">PMC8270965</ArticleId><ArticleId IdType="pubmed">34244497</ArticleId></ArticleIdList></Reference><Reference><Citation>Brozzetti L., Sacchetto L., Cecchini M.P., Avesani A., Perra D., Bongianni M., Portioli C., Scupoli M., Ghetti B., Monaco S., Buffelli M., Zanusso G. Neurodegeneration-Associated Proteins in Human Olfactory Neurons Collected by Nasal Brushing. Front. Neurosci. 2020;14 doi: 10.3389/fnins.2020.00145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00145</ArticleId><ArticleId IdType="pmc">PMC7066258</ArticleId><ArticleId IdType="pubmed">32194369</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R., von Bartheld C.S. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist. 2021;27:582&#x2013;603. doi: 10.1177/1073858420956905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858420956905</ArticleId><ArticleId IdType="pmc">PMC7488171</ArticleId><ArticleId IdType="pubmed">32914699</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M.Y., Leslie F.M., Zhou Q.Y. Expression of prokineticins and their receptors in the adult mouse brain. J. Comp. Neurol. 2006;498:796&#x2013;809. doi: 10.1002/CNE.21087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/CNE.21087</ArticleId><ArticleId IdType="pmc">PMC2667319</ArticleId><ArticleId IdType="pubmed">16927269</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuesta M.C., Quintero L., Pons H., Suarez-Roca H. Substance P and calcitonin gene-related peptide increase IL-1&#x3b2;, IL-6 and TNF&#x3b1; secretion from human peripheral blood mononuclear cells. Neurochem. Int. 2002;40:301&#x2013;306. doi: 10.1016/S0197-0186(01)00094-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(01)00094-8</ArticleId><ArticleId IdType="pubmed">11792459</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., Brenner M.J., De Luca P., Albanese M., D&#x2019;Ascanio L., Ralli M., Roccamatisi D., Cingolani C., Vitelli F., Camaioni A., Di Girolamo S., Bernitsas E. Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study. Brain Sci. 2022;12(2):154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8870047</ArticleId><ArticleId IdType="pubmed">35203918</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., Severini C., Colizza A., De Vincentiis M., La Mantia I. Investigational drugs for the treatment of olfactory dysfunction. Expert Opin. Invest. Drugs. 2022;31(9):945&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">35983993</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty R.L. Olfactory dysfunction in COVID-19: pathology and long-term implications for brain health. Trends Mol. Med. 2022;28:781&#x2013;794. doi: 10.1016/J.MOLMED.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MOLMED.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9212891</ArticleId><ArticleId IdType="pubmed">35810128</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito F., Cirillo M., De Micco R., Caiazzo G., Siciliano M., Russo A.G., Monari C., Coppola N., Tedeschi G., Tessitore A. Olfactory loss and brain connectivity after COVID-19. Hum. Brain Mapp. 2022;43:1548&#x2013;1560. doi: 10.1002/HBM.25741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/HBM.25741</ArticleId><ArticleId IdType="pmc">PMC8886650</ArticleId><ArticleId IdType="pubmed">35083823</ArticleId></ArticleIdList></Reference><Reference><Citation>Finger T.E., B&#xf6;ttger B., Schaefer M.L., Silver W.L. Trigeminal collaterals in the nasal epithelium and olfactory bulb: A potential route for direct modulation of olfactory information by trigeminal stimuli. J. Comp. Neurol. 2002;444:221&#x2013;226. doi: 10.1002/CNE.10143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/CNE.10143</ArticleId><ArticleId IdType="pubmed">11840476</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluegge D., Moeller L.M., Cichy A., Gorin M., Weth A., Veitinger S., Cainarca S., Lohmer S., Corazza S., Neuhaus E.M., Baumgartner W., Spehr J., Spehr M. Mitochondrial Ca(2+) mobilization is a key element in olfactory signaling. Nat. Neurosci. 2012;15:754&#x2013;762. doi: 10.1038/NN.3074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/NN.3074</ArticleId><ArticleId IdType="pubmed">22446879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon R., Neal M.L., Luo J., Langley M.R., Harischandra D.S., Panicker N., Charli A., Jin H., Anantharam V., Woodruff T.M., Zhou Q.Y., Kanthasamy A.G., Kanthasamy A. Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nat. Commun. 2016;7:1&#x2013;18. doi: 10.1038/ncomms12932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12932</ArticleId><ArticleId IdType="pmc">PMC5059486</ArticleId><ArticleId IdType="pubmed">27703142</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanf G., Schierhorn K., Brunn&#xe9;e T., Noga O., Verges D., Kunkel G. Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis. Inflamm. Res. 2000;49:520&#x2013;523. doi: 10.1007/S000110050625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S000110050625</ArticleId><ArticleId IdType="pubmed">11089903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hintschich C.A., Vielsmeier V., Bohr C., Hagemann J., Klimek L. Prevalence of acute olfactory dysfunction differs between variants of SARS-CoV-2&#x2014;results from chemosensitive testing in wild type, VOC alpha (B.1.1.7) and VOC delta (B.1617.2) Eur. Arch. Oto-Rhino-Laryngol. 2022;279(11):5445&#x2013;5447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9243797</ArticleId><ArticleId IdType="pubmed">35767061</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, M.B., Young, A.D., Marriott, I., Wang, H., Fernandes, A., Arturo Garc&#xed;a-Horsman, J., Hughes, Z., 2017. The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders. https://doi.org/10.3389/fncel.2016.00296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5209380</ArticleId><ArticleId IdType="pubmed">28101005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattanzi R., Miele R. Prokineticin-Receptor Network: Mechanisms of Regulation. Life. 2022;12(2):172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877203</ArticleId><ArticleId IdType="pubmed">35207461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattanzi R., Maftei D., Negri L., Fusco I., Miele R. PK2&#x3b2; ligand, a splice variant of prokineticin 2, is able to modulate and drive signaling through PKR1 receptor. Neuropeptides. 2018;71:32&#x2013;42. doi: 10.1016/J.NPEP.2018.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NPEP.2018.06.005</ArticleId><ArticleId IdType="pubmed">30253862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattanzi R., Maftei D., Petrella C., Pieri M., Sancesario G., Schirinzi T., Bernardini S., Barbato C., Ralli M., Greco A., Possenti R., Sancesario G., Severini C. Involvement of the Chemokine Prokineticin-2 (PROK2) in Alzheimer&#x2019;s Disease: From Animal Models to the Human Pathology. Cells. 2019;8(11):1430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6912774</ArticleId><ArticleId IdType="pubmed">31766244</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattanzi R., Severini C., Maftei D., Saso L., Badiani A. The Role of Prokineticin 2 in Oxidative Stress and in Neuropathological Processes. Front. Pharmacol. 2021 doi: 10.3389/fphar.2021.640441.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.640441</ArticleId><ArticleId IdType="pmc">PMC7956973</ArticleId><ArticleId IdType="pubmed">33732160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucero M.T. Peripheral modulation of smell: Fact or fiction? Seminars Cell Develop. Biol. 2013;24(1):58&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546122</ArticleId><ArticleId IdType="pubmed">22986099</ArticleId></ArticleIdList></Reference><Reference><Citation>Maftei D., Schirinzi T., Mercuri N.B., Lattanzi R., Severini C. Potential Clinical Role of Prokineticin 2 (PK2) in Neurodegenerative Diseases. Curr. Neuropharmacol. 2022;20(11):2019&#x2013;2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9886845</ArticleId><ArticleId IdType="pubmed">35410604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mashaghi A., Marmalidou A., Tehrani M., Grace P.M., Pothoulakis C., Dana R. Neuropeptide substance P and the immune response. Cell. Mol. Life Sci. 2016;73:4249&#x2013;4264. doi: 10.1007/S00018-016-2293-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00018-016-2293-Z</ArticleId><ArticleId IdType="pmc">PMC5056132</ArticleId><ArticleId IdType="pubmed">27314883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehboob R. Neurokinin-1 Receptor as a potential drug target for COVID-19 treatment. Biomed. Pharmacother. 2021;143:112159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8435369</ArticleId><ArticleId IdType="pubmed">34536760</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehboob, R., Ahmad, F.J., Qayyum, A., Rana, M.A., Gilani, S.A., Tariq, M.A., Akram, J., 2020. Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach. medRxiv 2020.08.01.20166678. https://doi.org/10.1101/2020.08.01.20166678.</Citation></Reference><Reference><Citation>Neal M., Luo J., Harischandra D.S., Gordon R., Sarkar S., Jin H., Anantharam V., D&#xe9;saubry L., Kanthasamy A., Kanthasamy A. Prokineticin-2 promotes chemotaxis and alternative A2 reactivity of astrocytes. Glia. 2018;66:2137&#x2013;2157. doi: 10.1002/GLIA.23467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/GLIA.23467</ArticleId><ArticleId IdType="pmc">PMC6240381</ArticleId><ArticleId IdType="pubmed">30277602</ArticleId></ArticleIdList></Reference><Reference><Citation>Negri L., Ferrara N. The prokineticins: Neuromodulators and mediators of inflammation and myeloid cell-dependent angiogenesis. Physiol. Rev. 2018;98:1055&#x2013;1082. doi: 10.1152/physrev.00012.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00012.2017</ArticleId><ArticleId IdType="pubmed">29537336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K.L., Li J.-D., Cheng M.Y., Leslie F.M., Lee A.G., Zhou Q.-Y. Dependence of Olfactory Bulb Neurogenesis on Prokineticin 2 Signaling. Science (80-) 2005;308:1923&#x2013;1927. doi: 10.1126/SCIENCE.1112103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.1112103</ArticleId><ArticleId IdType="pubmed">15976302</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A., Albanese M., Marrone G., Di Lauro M., Pietroboni Zaitseva A., Palazzetti D., Guerriero C., Paolino A., Pizzenti G., Di Daniele F., Romani A., D&#x2019;Agostini C., Magrini A., Mercuri N.B., Di Daniele N. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. Pharmaceuticals (Basel) 2021;14(4):336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8067485</ArticleId><ArticleId IdType="pubmed">33917573</ArticleId></ArticleIdList></Reference><Reference><Citation>Olpe H.R., Heid J., Bittiger H., Steinmann M.W. Substance P depresses neuronal activity in the rat olfactory bulb in vitro and in vivo: possible mediation via gamma-aminobutyric acid release. Brain Res. 1987;412:269&#x2013;274. doi: 10.1016/0006-8993(87)91133-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(87)91133-4</ArticleId><ArticleId IdType="pubmed">2440522</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr&#xfa; C.D., Bongianni M., Tonoli G., Ferrari S., Hughson A.G., Groveman B.R., Fiorini M., Pocchiari M., Monaco S., Caughey B., Zanusso G. A Test for Creutzfeldt-Jakob Disease Using Nasal Brushings. N. Engl. J. Med. 2014;371:519&#x2013;529. doi: 10.1056/NEJMOA1315200/SUPPL_FILE/NEJMOA1315200_DISCLOSURES.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA1315200/SUPPL_FILE/NEJMOA1315200_DISCLOSURES.PDF</ArticleId><ArticleId IdType="pmc">PMC4186748</ArticleId><ArticleId IdType="pubmed">25099576</ArticleId></ArticleIdList></Reference><Reference><Citation>Passali G.C., Passali D., Cingi C., Ciprandi G. Smell impairment in patients with chronic rhinosinusitis: a real-life study. Eur. Arch. Otorhinolaryngol. 2022;279(2):773&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">33942122</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinoso-Arija R., L&#xf3;pez-Ram&#xed;rez C., Jimenez-Ruiz J.A., L&#xf3;pez-Campos J.L. Effectiveness of aprepitant in post-acute COVID19 syndrome. Clin. Case Rep. 2021;9:e04646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8449093</ArticleId><ArticleId IdType="pubmed">34567551</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumeau C., Nguyen D.T., Jankowski R. How to assess olfactory performance with the Sniffin&#x2019; Sticks test&#xae;. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2016;133:203&#x2013;206. doi: 10.1016/J.ANORL.2015.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.ANORL.2015.08.004</ArticleId><ArticleId IdType="pubmed">26344139</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T., Landi D., Liguori C. COVID-19: dealing with a potential risk factor for chronic neurological disorders. J. Neurol. 2021;268(4):1171&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7450256</ArticleId><ArticleId IdType="pubmed">32852580</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T., Maftei D., Pieri M., Bernardini S., Mercuri N.B., Lattanzi R., Severini C. Increase of Prokineticin-2 in Serum of Patients with Parkinson&#x2019;s Disease. Mov. Disord. 2021;36(4):1031&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">33404134</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T., Maftei D., Ralli M., Greco A., Mercuri N.B., Lattanzi R., Severini C. Serum Substance P Is Increased in Parkinson&#x2019;s Disease and Correlates with Motor Impairment. Mov. Disord. 2021 doi: 10.1002/MDS.28824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/MDS.28824</ArticleId><ArticleId IdType="pubmed">34623702</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirinzi T., Maftei D., Passali F.M., Grillo P., Zenuni H., Mascioli D., Maurizi R., Loccisano L., Vincenzi M., Rinaldi A.M., Ralli M., Prof S.D.G., Stefani A., Lattanzi R., Severini C., Mercuri Prof N.B. Olfactory neuron Prokineticin-2 as a potential target in Parkinson&#x2019;s disease. Ann. Neurol. 2022 doi: 10.1002/ANA.26526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ANA.26526</ArticleId><ArticleId IdType="pubmed">36218142</ArticleId></ArticleIdList></Reference><Reference><Citation>Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., Erspamer V. The tachykinin peptide family. Pharmacol. Rev. 2002;54:285&#x2013;322. doi: 10.1124/PR.54.2.285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/PR.54.2.285</ArticleId><ArticleId IdType="pubmed">12037144</ArticleId></ArticleIdList></Reference><Reference><Citation>Steelant B., Hox V., Van Gerven L., Dilissen E., Dekimpe E., Kasran A., Aertgeerts S., Van Belle V., Peers K., Dupont L.J., Hellings P.W., Bullens D.M., Seys S.F. Nasal symptoms, epithelial injury and neurogenic inflammation in elite swimmers. Rhinology. 2018;56:279&#x2013;287. doi: 10.4193/RHIN17.167.</Citation><ArticleIdList><ArticleId IdType="doi">10.4193/RHIN17.167</ArticleId><ArticleId IdType="pubmed">29561921</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani A., Iranzo A., Holzknecht E., Perra D., Bongianni M., Gaig C., Heim B., Serradell M., Sacchetto L., Garrido A., Capaldi S., S&#xe1;nchez-G&#xf3;mez A., Cecchini M.P., Mariotto S., Ferrari S., Fiorini M., Schmutzhard J., Cocchiara P., Vilaseca I., Brozzetti L., Monaco S., Jose Marti M., Seppi K., Tolosa E., Santamaria J., H&#xf6;gl B., Poewe W., Zanusso G. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain. 2021;144:1118&#x2013;1126. doi: 10.1093/brain/awab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab005</ArticleId><ArticleId IdType="pubmed">33855335</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B.K.J., Han R., Zhao J.J., Tan N.K.W., Quah E.S.H., Tan C.J.W., Chan Y.H., Teo N.W.Y., Charn T.C., See A., Xu S., Chapurin N., Chandra R.K., Chowdhury N., Butowt R., Von Bartheld C.S., Kumar B.N., Hopkins C., Toh S.T. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022;378 doi: 10.1136/BMJ-2021-069503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ-2021-069503</ArticleId><ArticleId IdType="pmc">PMC9326326</ArticleId><ArticleId IdType="pubmed">35896188</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavano F., Palmieri O., di Mola F.F., Latiano A., Burbaci F.P., Valvano M.R., Corritore G., Augello B., Merla G., Annese V., Andriulli A., di Sebastiano P. Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases. Dig. Liver Dis. 2013;45:1003&#x2013;1010. doi: 10.1016/J.DLD.2013.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.DLD.2013.05.010</ArticleId><ArticleId IdType="pubmed">23827863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirassa P., Schirinzi T., Raspa M., Ralli M., Greco A., Polimeni A., Possenti R., Mercuri N.B., Severini C. What substance P might tell us about the prognosis and mechanism of Parkinson&#x2019;s disease? Neurosci. Biobehav. Rev. 2021;131:899&#x2013;911. doi: 10.1016/J.NEUBIOREV.2021.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.NEUBIOREV.2021.10.008</ArticleId><ArticleId IdType="pubmed">34653503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah M.W., Bano F., Rashid F., Mehboob R., Kurdi M., Bamaga A., Aldardeir N., Nasief H., Moshref L.H., Alsinani T., Rayes A.O., Jabbad R.H. Substance P/ Neurokinin-1 Receptor, Trigeminal Ganglion, Latency, and Coronavirus Infection-Is There Any Link? Front. Med. 2021;8 doi: 10.3389/fmed.2021.727593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.727593</ArticleId><ArticleId IdType="pmc">PMC8637107</ArticleId><ArticleId IdType="pubmed">34869423</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaira L.A., Lechien J.R., Deiana G., Salzano G., Maglitto F., Piombino P., Mazzatenta A., Boscolo-Rizzo P., Hopkins C., De Riu G. Prevalence of olfactory dysfunction in D614G, alpha, delta and omicron waves: a psychophysical case-control study. Rhinology. 2022;0(0)</Citation><ArticleIdList><ArticleId IdType="pubmed">36272169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Chu C.H., Qian L., Chen S.H., Wilson B., Oyarzabal E., Jiang L., Hong J.S., Ali S., Robinson B., Kim H.C. Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase. J. Neurosci. 2014;34:12490&#x2013;12503. doi: 10.1523/JNEUROSCI.2238-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2238-14.2014</ArticleId><ArticleId IdType="pmc">PMC4160779</ArticleId><ArticleId IdType="pubmed">25209287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y., Zhang Z., Li Z., Liu G., Tao G., Song X., Xu Z., Shang Z., Guo T., Su Z., Chen H., You Y., Li J., Yang Z. The PROK2/PROKR2 signaling pathway is required for the migration of most olfactory bulb interneurons. J. Comp. Neurol. 2019;527:2931&#x2013;2947. doi: 10.1002/CNE.24719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/CNE.24719</ArticleId><ArticleId IdType="pubmed">31132148</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>